NCT04909515撤回2 期
Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GMCSF) and Isotretinoin for Consolidation of Patients With High-Risk Neuroblastoma in First Remission. An International, Open-Label,Uncontrolled, Single-Arm, Multicenter, Phase 2 Trial
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 撤回
- 试验地点
- 9
- 主要终点
- 2-year progression free survival (PFS)
研究概览
简要总结
This is a single-arm, uncontrolled, international, multi-center, clinical,phase 2 trial, in patients ≥ 12 months of age with high-risk neuroblastoma in first remission. 120 patients will be enrolled to receive naxitamab + GM-CSF in combination with isotretinoin.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 1 Year 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Documentet neuroblastoma at time of diagnosis defined as
- •Histopathology of solid tumor biopsy, or
- •Bone marrow aspirate or biopsy indicative of neuroblastoma plus high blood or urine catecholamine metabolite levels
- •Documented high-risk disease at time of initial diagnosis defined as
- •MYNC-amplified at stage L2, M or MS (according to International Neuroblastoma Risk Group (INRG)) of any age or
- •MYCN-nonamplified with stage M (according to INRG) and diagnosed at ≥ 18 months of age or
- •Patient must have completed frontline therapy, and achieved one of the following:
- •verified complete response according to INRC (bone marrow positive minimal residual disease is allowed as assessed by RTqPCR at site) after completion of induction and consolidation with or without autologous stem cell transplantation
- •Verified partial response according to INRC for primary site and soft tissue, bone, and bone marrow metastases at pre-autologous stem cell transplantation evaluation (i.e., myeloablative chemotherapy + autologous stem cell transplantation required as part of frontline regimen). Furthermore, bone marrow response must be with ≤ 5% tumor (of total nucleated cellular content) seen on any specimen from a bilateral bone marrow aspirate/biopsy and bone response must be with ≤ 3 areas of abnormal uptake on 123I-MIBG scintigraphy
- •Age ≥ 12 months at trial enrollment
排除标准
- •Verified progressive disease during induction or consolidation therapy
- •Any systemic anti-cancer therapy, including chemotherapy, within 3 weeks prior to enrollment
- •Autologous stem cell transplantation within 6 weeks prior to enrollment or ongoing toxicity caused by the autologous stem cell transplantation at the discretion of the Investigator
- •Therapeutic 131I-MIBG within 6 weeks prior to enrollment
- •Prior anti-GD2 therapy
- •Performance status of < 50% as per the Lansky scale (patients less than 16 years of age) or Karnofsky scale (patients aged 16 years or older)
研究组 & 干预措施
naxitamab + GM-CSF + isotretinoin
Experimental
8 cycles. Cycles 1+2 naxitamab + GM-CSF, cycles 3-5 naxitamab + GM-CSF + isotretinoin, cycles 6-8 isotretinoin
干预措施: Naxitamab (Drug)
naxitamab + GM-CSF + isotretinoin
Experimental
8 cycles. Cycles 1+2 naxitamab + GM-CSF, cycles 3-5 naxitamab + GM-CSF + isotretinoin, cycles 6-8 isotretinoin
干预措施: GM-CSF (Drug)
naxitamab + GM-CSF + isotretinoin
Experimental
8 cycles. Cycles 1+2 naxitamab + GM-CSF, cycles 3-5 naxitamab + GM-CSF + isotretinoin, cycles 6-8 isotretinoin
干预措施: Isotretinoin (Drug)
结局指标
主要结局
2-year progression free survival (PFS)
时间窗: 2 years
2-year PFS defined as the proportion of patients alive and without progressive disease (PD) or relapse 2 years after enrollment
次要结局
- 1-year and 2-year overall survival(2 years)
- 2-year event-free survival(2 years)
- Proportion of positive to negative minimal residual disease (MRD) after 2 cycles(6 weeks)
- 1-year progression free survival(1 year)
- Proportion of patients with MD positive convert to MRD negative(6 weeks)
- Progression free survival(128 weeks)
研究者
研究点 (9)
Loading locations...
相似试验
终止
2 期
Naxitamab and GM-CSF in Combination With IT in Patients With High-Risk NeuroblastomaNeuroblastoma RecurrentNCT04560166Y-mAbs Therapeutics2
已完成
2 期
A Study Of Naxitamab , Granulocyte Macrophage Colony Stimulating Factor For Patients With Relapsed /Refractory , Soft Tissue or Anti GD2 Immunotherapy Refractory NeuroblastomaRefractory NeuroblastomaSoft Tissue CancerNCT06438614Fundació Sant Joan de Déu47
尚未招募
4 期
Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) Combined With Isotretinoin for Maintenance Treatment of Patients With High-Risk Neuroblastoma in First Complete Response.NeuroblastomaNCT06047535SciClone Pharmaceuticals62
招募中
2 期
To Evaluate the Efficacy and Safety of Naxitamab in Patients With Refractory Ewing's Sarcoma (Butterfly)Ewing SarcomaNCT05968768Anna Raciborska24
招募中
1 期
Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast CancerHER2-Negative Breast CarcinomaNCT06026657Margaret Gatti-Mays42